BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 31263025)

  • 21. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson's disease.
    Koentjoro B; Park JS; Sue CM
    Sci Rep; 2017 Mar; 7():44373. PubMed ID: 28281653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
    Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
    Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis.
    Nishikawa Y; Kodama Y; Shiokawa M; Matsumori T; Marui S; Kuriyama K; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Sakuma Y; Ota Y; Maruno T; Uza N; Uesugi M; Kageyama R; Chiba T; Seno H
    Oncogene; 2019 May; 38(22):4283-4296. PubMed ID: 30705405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation.
    Loncle C; Molejon MI; Lac S; Tellechea JI; Lomberk G; Gramatica L; Fernandez Zapico MF; Dusetti N; Urrutia R; Iovanna JL
    Cell Death Dis; 2016 Jul; 7(7):e2295. PubMed ID: 27415425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow Cytometer Monitoring of Bnip3- and Bnip3L/Nix-Dependent Mitophagy.
    Šprung M; Dikic I; Novak I
    Methods Mol Biol; 2018; 1759():105-110. PubMed ID: 28324488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
    Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice.
    Young CC; Baker RM; Howlett CJ; Hryciw T; Herman JE; Higgs D; Gibbons R; Crawford H; Brown A; Pin CL
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):93-113. PubMed ID: 30510993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
    Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.
    Garcia MN; Grasso D; Lopez-Millan MB; Hamidi T; Loncle C; Tomasini R; Lomberk G; Porteu F; Urrutia R; Iovanna JL
    J Clin Invest; 2014 Nov; 124(11):4709-22. PubMed ID: 25250570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
    Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
    Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice.
    Habbe N; Shi G; Meguid RA; Fendrich V; Esni F; Chen H; Feldmann G; Stoffers DA; Konieczny SF; Leach SD; Maitra A
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18913-8. PubMed ID: 19028870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical KRAS
    Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
    Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
    Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
    Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
    Fujimura K; Wang H; Watson F; Klemke RL
    Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SWI/SNF component
    Wang SC; Nassour I; Xiao S; Zhang S; Luo X; Lee J; Li L; Sun X; Nguyen LH; Chuang JC; Peng L; Daigle S; Shen J; Zhu H
    Gut; 2019 Jul; 68(7):1259-1270. PubMed ID: 30315093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall survival of pancreatic ductal adenocarcinoma is doubled by
    Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
    Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.